Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9831322 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1TP53TSHRMAPK1 | |
| SCHEMBL9829571 | 0.98 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1TP53TSHRMAPK1 | |
| SCHEMBL7890180 | 0.98 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1TP53TSHRMAPK1 | |
| SCHEMBL23441779 | 0.96 | TP53 (0.57) | SMN1; SMN2ALDH1A1TP53TSHRMAPK1 | |
| SCHEMBL25044588 | 0.92 | TP53 (0.65) | SMN1; SMN2ALDH1A1TP53TSHRMAPK1 | |
| SCHEMBL1951920 | 0.92 | TP53 (0.65) | SMN1; SMN2ALDH1A1TP53TSHRMAPK1 | |
| SCHEMBL7898085 | 0.92 | TSHR (0.56) | SMN1; SMN2ALDH1A1TP53TSHRMAPK1 | |
| SCHEMBL9831740 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1TP53TSHRMAPK1 | |
| SCHEMBL9831734 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1TP53TSHRMAPK1 | |
| SCHEMBL6139318 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1TP53TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11692008-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | XWPharma Ltd. (KY) | 2023-07-04 | — | — | US | disclosed |
| US-6180140-B1 | SUITABLE FOR ORAL ADMINISTRATION OF BIOLOGICALLY ACTIVE AGENTS TO ANIMALS | EMISPHERE TECHNOLOGIES, INC. | 2001-01-30 | — | — | US | disclosed |
| US-5935601-A | Modified amino acids for drug delivery | EMISPHERE TECHNOLOGIES, INC. (US) | 1999-08-10 | — | — | US | disclosed |
| EP-0812212-A4 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECH INC (US) | 1999-04-14 | — | — | EP | disclosed |
| US-5709861-A | PEPTIDES WITH ANTIGENS AND PROCESS FOR MIXING | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-01-20 | — | — | US | disclosed |
| EP-0812212-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | Emisphere Technologies, Inc. (US) | 1997-12-17 | — | — | EP | disclosed |
| US-5629020-A | Modified amino acids for drug delivery | EMISPHERE TECHNOLOGIES, INC. (US) | 1997-05-13 | — | — | US | disclosed |
| WO-1996021464-A9 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | — | 1996-11-14 | — | — | WO | disclosed |
| WO-1996021464-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECHNOLOGIES, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11692008-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | AIFM2, GPX1, GPX4 | SMN1; SMN2 2497/4885ALDH1A1 462/4885TP53 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.